FDA 483 - TAIWAN BIOTECH CO., LTD. - September 20, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of TAIWAN BIOTECH CO., LTD. in Taoyuan City, Taiwan, a sterile drug manufacturer, revealed significant deficiencies in their quality control unit and stability testing programs. Observations included unqualified vendors, non-contemporaneous record-keeping, inadequate CAPA management, and issues with incubator qualification and monitoring. Additionally, the firm failed to properly utilize stability testing results for determining appropriate storage conditions and expiration dates for their sterile drug products.
ID · 1f9e54e0-1c99-4d74-be28-1fb24a91ed04